The FDA is signaling change, but actual success depends on more than simply bringing in a new leader at the Center for ...
The Durham plant will manufacture immunology, neuroscience and oncology drugs once AbbVie finishes construction in 2028.
Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight ...
Approved Thursday via the FDA's Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for ...
Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s ...
Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes ...
This year’s American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for ...
Looking for a biopharma job in Illinois? Check out the BioSpace list of 11 companies hiring life sciences professionals like ...
The FDA in July 2025 made publicly available over 200 complete response letters—an initiative that the investment community ...
Women and nonwhite racial/ethnic groups are still earning less in the life sciences. An industry consultant discusses the pay ...
The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the ...
The deals keep rolling in, with Lilly penning a $7 billion pact for gene delivery biotech Kelonia Therapeutics and UCB taking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results